Clinical Trials Browser

Phase 1 × Leukemia, Myeloid, Chronic-Phase × Surveys and Questionnaires × Clear all

NCT02225574 2020-02-12

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Phase 1 Terminated

Other hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Chronic-Phase